索塔格利弗洛辛:用一块石头打两只小鸟?
Juan Antonio Requena-Ibáñez1, Kristine Mørk Kindberg2,3, Carlos G Santos-Gallego4
1Atherothrombosis Research Unit, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Pl., New York, NY, 10029-0310, USA. juanantonio.requenaibanez@mssm.edu.
Cardiovascular drugs and therapy
|June 4, 2025
概括
双重SGLT1-2抑制剂,如索塔格利弗洛辛,在减少主要心血管不良事件,包括心脏病发作和中风方面表现有前途,可能为心力衰竭患者提供比单独使用SGLT2抑制剂更大的益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- -葡萄糖携带载体2抑制剂 (SGLT2i) 是已确立的心力衰竭 (HF) 治疗方法,可以减少主要心血管不良事件 (MACE).
- SGLT2i不会显著影响心肌梗塞 (MI) 或中风等动脉血事件.
- 索塔格利弗洛辛是一种SGLT1和SGLT2的新型双重抑制剂.
研究的目的:
- 为了比较双 SGLT1-2 抑制与单独 SGLT2 抑制对心血管的益处.
- 探索SGLT1在心血管病理生理学中的作用及其作为治疗点的潜力.
- 评估索塔格利弗洛辛对MACE,MI和中风的影响.
主要方法:
- 对过去五年内发表的研究进行了全面的文献审查.
- 搜索的数据库包括PubMed和Scopus.
- 文章的选择是基于相关性,方法质量和引用影响.
主要成果:
- SGLT1和SGLT2在葡萄糖再吸收中具有共同的作用,而SGLT1也参与肠道葡萄糖吸收.
- 在失败的心脏中,SGLT1过度表达,导致氧化应激,心肌细胞缩和纤维化.
- 索塔格利弗洛辛对SGLT1的抑制可能会逆转心脏中有害的代谢变化,并减少血小板激活.
- 索塔格利弗洛辛证明了MACE,MI和中风的减少,与单独的SGLT2i不同.
结论:
- 双 SGLT1-2 抑制可能提供除了 SGLT2 抑制之外的额外心血管益处.
- 需要进一步的研究来阐明SGLT2i与SGLT1-2i.i.的不同临床影响.
- 对比和机制研究是必不可少的,特别是在心力衰竭的非糖尿病患者中.
相关概念视频
Oral Hypoglycemic Agents: Glinides
837
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
837
Dipeptidyl Peptidase 4 Inhibitors
895
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
895
Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
830
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
830
Oral Hypoglycemic Agents: Sulfonylureas
1.5K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
770
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
770


